Analysis of 3297 individuals suggests that the pathogenic germline 5′-UTR variant BRCA1 c.-107A > T is not common in south-east Germany
- 21 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Familial Cancer
- Vol. 19 (3), 211-213
- https://doi.org/10.1007/s10689-020-00175-4
Abstract
In this study we aim to determine the prevalence of the recently identified pathogenic BRCA1 variant c.-107A > T in the south-east German population. This variant causes the epigenetic silencing of the BRCA1 promotor and has been detected in two independent families from the UK without a germline BRCA1 or BRCA2 pathogenic variant. A total of 3297 individuals with suspicion of hereditary breast and ovarian cancer and fulfilling the clinical criteria necessary for genetic testing in Germany were analyzed for presence of the variant by a Kompetitive Allele-Specific PCR (KASP) assay or direct Sanger sequencing. Since we did not detect an individual carrying the variant we conclude that BRCA1 c.-107A > T is not a common variant in the south-east German population.Keywords
This publication has 10 references indexed in Scilit:
- Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer SubtypesAmerican Journal of Human Genetics, 2019
- A Dominantly Inherited 5′ UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian CancerAmerican Journal of Human Genetics, 2018
- Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testingEuropean Journal of Human Genetics, 2016
- Prevalence ofBRCA1/2germline mutations in 21 401 families with breast and ovarian cancerJournal of Medical Genetics, 2016
- Critical research gaps and translational priorities for the successful prevention and treatment of breast cancerBreast Cancer Research, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialThe Lancet, 2010
- Genetic Predisposition to Breast Cancer: Past, Present, and FutureAnnual Review of Genomics and Human Genetics, 2008
- The Relative Contribution of Point Mutations and Genomic Rearrangements in BRCA1 and BRCA2 in High-Risk Breast Cancer FamiliesCancer Research, 2008
- Deletions Account for 17% of Pathogenic Germline Alterations in MLH1 and MSH2 in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) FamiliesGenetic Testing, 2005